MKMichael Keane

Michael Keane

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michael Keane has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Hydroxychloroquine with or without Azithromycin in Covid-19

    by Michael J. Keane

    Cavalcanti et al. (Nov. 19 issue)1 stated in the originally published Supplementary Appendix of their article (a corrected version is available at NEJM.org) that the use of “hydroxychloroquine and macrolides rapidly became part of the routine care of patients with Covid-19 [coronavirus disease 2019] in Brazil” during their trial, such that, as they stated in the originally published version of their article, “enrollment of patients with no previous use of these medications was challenging.”2 Preenrollment use of these medications was not an exclusion criterion until a change in their trial protocol (available at NEJM.org) was made 5 days before the last patient underwent randomization, yet only 7.5% of the patients in the modified intention-to-treat analysis had received hydroxychloroquine before enrollment (Table S3 in their Supplementary Appendix). In contrast, 35.8% of the patients had received azithromycin. Consecutive eligible patients were not recruited.2 Instead, an active-screening process was used that was not defined. The number of patients who underwent screening and the number who were excluded from the trial, as well as the reasons for exclusion, are important data that are not included in the CONSORT (Consolidated Standards of Reporting Trials) diagram (Fig. S1).


  • Open Access

    Hydroxychloroquine, Parachutes And How to Understand 'The Evidence'

    by Michael Keane

    It is deliberately misleading to make general claims that hydroxychloroquine doesn’t work for CoViD-19. It is even more misleading to claim that “the evidence” proves that hydroxychloroquine doesn’t work. To understand this, consider the use of parachutes. Consider someone who claimed that parachutes don’t work to stop death or serious injury when jumping out of a plane. What if they further claimed that “the evidence” proves that parachutes don’t work? Now consider if this same person advocated that because parachutes “don’t work”, we should ban their use and demanded that conscientious pilots who give a parachute to someone jumping out of a plane should lose their pilot’s license. Surely, such claims would be considered false and misleading. Two classic parodies, published in the British Medical Journal, showed that the above statements about parachutes are technically true. In 2003, a straight-faced literature search found no high quality, randomized, placebo-controlled trials of parachutes. The fact that people usually get squashed to smithereens when they hit the ground without a parachute was just epidemiological data. There’s no proof the parachute makes any difference. It could be due to confounding factors or bias. Subsequently, in 2018, a group of researchers actually did a randomized, placebo-controlled trial of the use of parachutes when jumping from a plane. There was no difference in death or serious injury in those who wore a parachute and those who didn’t. However, the participants jumped out of a plane 60cm off the ground while it was stationary. So, it would, or course, be misleading to make the claim that the “evidence says that parachutes don’t work.” That is, the general claim that parachutes “don’t work” cannot be derived from studies where they are not used in the situation where they can provide benefit. Of course, everyone is going to survive whether you give them a parachute or not when jumping from 60 cm. It is egregiously misleading, and it would be lethal, to deprive someone of a parachute when jumping from 10,000 feet based on a study that tested a parachute at 60 cm. Now let’s look at hydroxychloroquine. CoViD-19 is a disease with very different stages. And the vast majority of people, especially young people, are not going to die from CoViD-19. The suggestion from a significant amount of epidemiological data is that, if given early in the course of the disease, HCQ might prevent progression to critical illness or death in at-risk population groups. However, the randomized controlled trials (RCTs) performed to test the effect of hydroxychloroquine have been the equivalent of testing the effect of parachutes in the following circumstances: after a 60 cm jump; or pulling the rip-cord 2 feet above the ground after free-falling; or putting the parachute on someone after they hit the ground. Different RCTs on hydroxychloroquine have had variable characteristics including the following: control groups with average ages in the 30s and 40s; a cohort with 99% of patients with mild to moderate disease; a cohort with death rates of 0.4%; a cohort with zero incidence of death or mechanical ventilation; patients already on ventilators or even ECMO; patients having symptoms up to 14 days before being commenced on hydroxychloroquine; patients having symptoms an average of 16 days before commencement of hydroxychloroquine.

  • Open Access

    Legal Implications of Personal Protective Equipment Use When Treating Patients for COVID-19 (SARS-CoV-2)

    by Danuta Mendelson, Michael Keane, Mirko Bagaric, Cameron Graydon

    Front-line health care personnel, including anaesthetists, otolaryngologists, and other health professionals dealing with acute cases of coronavirus, face a high risk of infection and thus mortality. The scientific evidence establishes that to protect them, hospital protocols should require that wearing of the highest levels of personal protective equipment (PPE) be available for doctors and nurses performing aerosol-generating procedures, such as intubation, sputum induction, open suctioning of airways, bronchoscopy, etc. of COVID-19 patients. Although several international bodies have issued recommendations for a very high-level PPE to be used when these procedures are undertaken, the current PPE guidelines in Australia have tended to be more relaxed, and hospital authorities relying on them might not comply with legal obligations to their employee health care workers. Failure to provide high-level PPE in many hospitals is of concern for a large number of health care workers; this article examines the scientific literature on the topic and provides a legal perspective on hospital authorities’ possible liability in negligence.

  • Open Access

    COVID-19: Time to Rethink the Randomized Controlled Trial and Consider More Efficient and Ethical Ways of Gaining Clinical Knowledge

    by Michael Keane

    Many academics are advocating for the strict adherence to randomized controlled trials (RCTs) in order to find treatments for CoViD-19. The prevailing orthodoxy within the academic establishment is that we should not encourage the use of new treatments for CoViD-19 until those treatments have demonstrated statistically significant clinical benefits in an RCT. Until that point, only patients enrolled in clinical trials should have access to new treatments, no matter how promising the treatment and no matter whether the patient might otherwise be at high risk of death. However, the fundamentalist belief in the RCT fails to acknowledge the limitations of the RCT in a rapidly changing, highly complex, enormously combinatorial and evolving system in which knowledge is continually being generated by clinicians around the world; the situation during the CoViD-19 pandemic. For our patients’ sake, we need efficient and ethical means of both providing treatment and gaining knowledge during this pandemic. The RCT should not be eliminated, but it's primacy reconsidered. From an ethical perspective, discouraging or prohibiting access to off-label/compassionate-use therapies outside of the RCT creates the potential for large disequilibria of the needs of current and future patients, in addition to forsaken clinical information from wide-scale observation. Depending on the pre-test totality of all knowledge of a treatment, it is difficult to even know if the result of an RCT is a true or false result. And importantly, depending on the pre-test probability, the result of the RCT might only give marginal (or no) extra surety regarding the effect of the studied treatment. A crucial, existential concept related to knowledge acquisition is whether the cumulative observation of clinical effects without a control provides any useable information. The RCT attempts to isolate a variable using the scientific method. Yet there are systems constraints within acute clinical medicine regarding reproducibility, and this can significantly affect the fidelity of knowledge that the RCT is able to provide. In this regard, the RCT has proved to be disappointing in providing efficient clinical knowledge in acute care medicine over the decades. Even proponents of the RCT have conceded that there has been a paucity of large RCTs that have shown a clear beneficial treatment effect. A major funding body has de-prioritized the RCT. We are half a year into the lethal CoViD-19 pandemic. Yet, the RCT paradigm has seemingly contributed little and has significantly lagged behind rational treatment innovation guided by increasing understanding of the disease. One well publicized RCT demonstrated a clinical benefit for a drug that otherwise had a high pre-test probability of effect. However, many clinical units were already using this drug as part of their treatment protocols and were achieving highly competitive survival rates; saving lives through rational innovation while continuously updating knowledge of drug and disease-specific effects. Should patients be empowered with the complete accumulated knowledge of an intervention as part of informed consent, before enrolling in an RCT? To be sure, the RCT has a role. However, with it's history of being an inefficient clinical-knowledge-gaining paradigm, we should not necessarily wait for clinical trials before introducing reasoned treatment approaches for our most vulnerable CoViD-19 patients.


  • Open Access

    Legal Implications of Personal Protective Equipment Use When Treating Patients for COVID-19 (SARS-CoV-2)

    by Michael Keane, Danuta Mendelson, Mirko Bagaric, Cameron Graydon

    Front-line healthcare personnel, particularly anesthetists and others dealing with acute cases of coronavirus, face a high risk of infection and thus mortality. The scientific evidence establishes that to protect them, hospital protocols should require that wearing of the highest levels of personal protective equipment [PPE] be available for doctors and nurses performing intubation of COVID-19 patients. Although several international bodies have issued recommendations for a very high-level PPE to be used when intubation procedures are undertaken, the current PPE guidelines in Australia are more relaxed, and hospital authorities relying on them might not comply with legal obligations to their employee healthcare workers. Failure to provide high level PPE in many hospitals is of concern for large number of healthcare workers; this article examines the scientific literature on the topic and provides a legal perspective on hospital authorities’ possible liability in negligence.

  • Advancing women in medical leadership

    by Michael Keane

    Click on the article title to read more.

  • Accuracy of the Securetec DrugWipe 6s Ketamine device in detecting acute and residual salivary ketamine following a stepwise intravenous treatment protocol

    by Amie C. Hayley, Maja Green, Michael Keane, Panagiota Kostakis, Yahya Shehabi, Con K. K. Stough, Luke A. Downey

    To evaluate the sensitivity of the Securetec DrugWipe 6 S Ketamine device in detecting salivary ketamine, we administered three fixed, increasing sub-anaesthetic doses of intravenous ketamine solution to 20 participants using an open-label, within subjects’ protocol. Results indicated, at a cut-off level of 5 ng/mL for ketamine in oral fluid, the Securetec DrugWipe 6 S Ketamine device indicated a uniformly positive result for the presence of ketamine during the acute dosing phase where corresponding mean whole blood ketamine concentrations were 0.38 mg/L (dose 1), 0.48 mg/L (dose 2) and 0.82 mg/L (dose 3), respectively. At 2-hours post treatment, the positive detection rate was 85% where corresponding mean whole blood concentrations of ketamine were 0.21 mg/L. Device detection rate reduced to 40% at 4-hours post-treatment.


  • Primary prevention aspirin among the elderly: challenges in translating trial evidence to the clinic

    by J William McEvoy, Michael Keane, Justin Ng

    Introduction The ASPirin in Reducing Events in the Elderly trial (ASPREE), published in 2018, was a landmark randomised-controlled trial (RCT) that contributed important knowledge about primary cardiovascular disease (CVD) prevention among healthy older adults.1 ASPREE found that daily low-dose aspirin (LDA) does ...